MeiraGTx Q2 2026: $160.7M Net Income, Bota-vec Acquisition, and FDA Breakthrough Designation
MGTX has more than doubled off its 52-week low of $6.62 on light trading volume (0.3× avg).
Summary
MeiraGTx swung to a $160.7M Q2 profit, acquired bota-vec from J&J, and received FDA Breakthrough Therapy Designation for AAV2-hAQP1, with cash runway into H2 2028.
Key Events · Earnings and Guidance · MGTX
-
Q2 Net Income of $160.7M
Net income of $160.7M ($1.76 basic EPS) was reported for Q2 2026, compared to a net loss of $38.8M in Q2 2025, driven by $204.6M in related-party license revenue from the Hologen collaboration.
-
Bota-vec Acquisition Completed
All rights to bota-vec for XLRP were acquired from J&J for a $25M upfront payment, with J&J eligible for milestones and mid-teens royalties on global net sales.
-
FDA Breakthrough Therapy Designation
AAV2-hAQP1 received FDA Breakthrough Therapy Designation in March 2026 for radiation-induced xerostomia, supported by positive three-year Phase 1 AQUAx data.
-
Cash Runway Extended to H2 2028
Cash and cash equivalents of $143.2M as of June 30, 2026, plus $135M initial Oberland funding and $95M Hologen payment, provide runway into the second half of 2028.
Analysis · MGTX · Life Sciences
A dramatic swing to profitability marks the quarter, with net income of $160.7M driven by $204.6M in related-party license revenue from the Hologen collaboration. The company also completed the $25M acquisition of bota-vec from J&J, received FDA Breakthrough Therapy Designation for AAV2-hAQP1, and secured up to $400M from Oberland Capital. Cash runway extends into H2 2028. These are transformative events that fundamentally change the company's commercial trajectory.
At the time of this filing, MGTX was trading at $13.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.62 to $15.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.